Edwards Lifesciences

Edwards Lifesciences shows a solid competitive position with solid gross margins of 78.7%. However, some vulnerability to competitive pressure suggests the moat, while present, may face challenges. The business earns above-average returns but lacks the exceptional durability of the strongest moats.